RT Journal Article
SR Electronic
T1 Does screening for <em>Neisseria gonorrhoeae</em> and <em>Chlamydia trachomatis</em> affect the incidence of these infections in men who have sex with men taking HIV pre-exposure prophylaxis (PrEP)Results from a randomized, multicentre controlled trial (the Gonoscreen study)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.08.14.23294056
DO 10.1101/2023.08.14.23294056
A1 Vanbaelen, Thibaut
A1 Tsoumanis, Achilleas
A1 Florence, Eric
A1 Van Dijck, Christophe
A1 Huis in ‘t Veld, Diana
A1 Sauvage, Anne-Sophie
A1 Herssens, Natacha
A1 De Baetselier, Irith
A1 Rotsaert, Anke
A1 Verhoeven, Veronique
A1 Henrard, Sophie
A1 Van Herrewege, Yven
A1 Van den Bossche, Dorien
A1 Goffard, Jean-Christophe
A1 Padalko, Elizaveta
A1 Reyniers, Thijs
A1 Vuylsteke, Bea
A1 Hayette, Marie-Pierre
A1 Libois, Agnes
A1 Kenyon, Chris
YR 2023
UL http://medrxiv.org/content/early/2023/08/16/2023.08.14.23294056.abstract
AB Background Guidelines recommend three-site (urine, anal, pharynx) three-monthly (3X3 screening) screening for Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) in men who have sex with men (MSM) taking HIV pre-exposure prophylaxis (PrEP). We present the first randomized controlled trial to compare the effect of screening versus non-screening for NG/CT on the incidence of these infections in MSM taking PrEP.Methods A multicenter, randomized, controlled trial of 3X3 screening for NG/CT versus non-screening was conducted among MSM taking PrEP in five HIV reference centers in Belgium. Participants attended the PrEP clinics quarterly for 12 months. NG/CT was tested at each visit in both arms, but results were not provided to the non-screening arm. The primary outcome was the incidence rate (IR) of NG/CT infections in each arm, assessed in the per-protocol population. Non-inferiority of the non-screening arm was proven if the upper limit of the 95% confidence interval of the IR ratio (IRR) was lower than 1.25. The trial protocol was registered at clinicaltrials.gov (NCT04269434).Findings Between September 2020 and June 2021, 508 subjects were randomized to the 3X3 screening arm and 506 to the non-screening arm. The overall IR of NG/CT was 0.155 cases/100 person-days (95%CI 0.128-0.186) in the 3×3 screening arm and 0.205 (95%CI 0.171-0.246) in the non-screening arm. The IR was significantly higher in the non-screening arm (IRR 1.318, 95%CI 1.068-1.627). Participants in the non-screening arm had a higher incidence of CT infections and symptomatic CT infections. There were no significant differences in NG infections. Participants in the non-screening arm consumed significantly less antimicrobials. No serious adverse events were reported.Interpretation We failed to show that non-screening for NG/CT is non-inferior to 3-site 3-monthly screening in MSM taking PrEP in Belgium. However, screening was associated with higher antibiotic consumption and had no effect on the incidence of NG. Therefore, our findings do not provide strong support for screening for NG/CT in this population.Funding Belgian Healthcare Knowledge Center (KCE - INV18-1133)Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04269434Funding StatementThis study was funded by the Belgian Healthcare Knowledge Center (KCE - INV18-1133)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board of the Institute of Tropical Medicine (1360/20) and by the Ethics Committees of the University Hospital of Antwerp (20/27/377), Saint-Pierre University Hospital (20-07-05), Ghent University Hospital (BC-08167), Erasme University Hospital (P2020/321) and Liege University Hospital (2020-240).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAnonymized individual participant data and a data dictionary defining each field in the dataset can be shared on approval of a written request to the corresponding author and in agreement with ITM data sharing policy.